LEXINGTON, Mass., Aug. 3, 2017 /PRNewswire/ -- Aldeyra
Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage
biotechnology company devoted to treating inflammation, inborn
errors of metabolism, and other diseases related to aldehydes,
today announced that Todd C. Brady,
M.D., Ph.D., President and CEO of Aldeyra, will present at the 37th
Annual Canaccord Genuity Growth Conference on Thursday, August 10, 2017.
Event: 37th Annual Canaccord Genuity Growth
Conference
Date: Thursday, August 10,
2017
Time: 1:00 PM ET
Location: The InterContinental Hotel, Boston, MA
A live webcast of the conference call will also be available on
the investor relations page of the Aldeyra Therapeutics corporate
website at www.aldeyra.com. After the live webcast, the
event will remain archived on the Aldeyra Therapeutics website.
About Aldeyra
Therapeutics
Aldeyra Therapeutics, Inc. is
a biotechnology company devoted to improving lives by inventing,
developing and commercializing products that treat diseases thought
to be related to endogenous aldehydes, a naturally occurring class
of pro-inflammatory and toxic molecules. Aldeyra's lead product
candidate, ADX-102, is an aldehyde trap in development for ocular
inflammation, as well as for Sjögren-Larsson Syndrome and Succinic
Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of
aldehyde metabolism. Aldeyra's product candidates have not been
approved for sale in the U.S. or elsewhere.
Corporate Contact:
Stephen Tulipano
Aldeyra Therapeutics, Inc.
Tel: +1 781-761-4904 ext. 205
stulipano@aldeyra.com
Investor Contact:
Chris Brinzey
Westwicke Partners
Tel: 339-970-2843
Chris.brinzey@westwicke.com
Media Contact:
Cammy Duong
MacDougall Biomedical Communications
781-591-3443
cduong@macbiocom.com
View original
content:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-to-present-at-the-37th-annual-canaccord-genuity-growth-conference-300498958.html
SOURCE Aldeyra Therapeutics, Inc.